190 related articles for article (PubMed ID: 26238440)
1. Phase I clinical trial of 99mTc-etarfolatide, an imaging agent for folate receptor in healthy Japanese adults.
Yamada Y; Nakatani H; Yanaihara H; Omote M
Ann Nucl Med; 2015 Nov; 29(9):792-8. PubMed ID: 26238440
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo evaluation of (99m)Tc-DO3A-EA-Folate for receptor-mediated targeting of folate positive tumors.
Mishra G; Hazari PP; Kumar N; Mishra AK
J Drug Target; 2011 Nov; 19(9):761-9. PubMed ID: 21425922
[TBL] [Abstract][Full Text] [Related]
3. Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging.
Maurer AH; Elsinga P; Fanti S; Nguyen B; Oyen WJ; Weber WA
J Nucl Med; 2014 May; 55(5):701-4. PubMed ID: 24732155
[TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab'.
Macfarlane DJ; Smart RC; Tsui WW; Gerometta M; Eisenberg PR; Scott AM
Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):648-56. PubMed ID: 16528525
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of isostructural Tc-99m- and Re-188-folate-Gly-Gly-Cys-Glu for folate receptor-positive tumor targeting.
Kim WH; Kim CG; Kim MH; Kim DW; Park CR; Park JY; Lee YS; Youn H; Kang KW; Jeong JM; Chung JK
Ann Nucl Med; 2016 Jun; 30(5):369-79. PubMed ID: 26993818
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of receptor-based tumor imaging agent: (99m)Tc-folate-glucaric acid.
Onursal M; Lambrecht FY; Ozgur A
Int J Pharm; 2011 Sep; 416(1):288-92. PubMed ID: 21782912
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical study with different doses of
Sun Y; Chen Z; Liu C; Tang J; Wang Y; Zhang G; Liu X
Ann Nucl Med; 2020 Mar; 34(3):212-219. PubMed ID: 32030559
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies.
Van de Wiele C; Dumont F; Dierckx RA; Peers SH; Thornback JR; Slegers G; Thierens H
J Nucl Med; 2001 Nov; 42(11):1722-7. PubMed ID: 11696645
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide).
Morris RT; Joyrich RN; Naumann RW; Shah NP; Maurer AH; Strauss HW; Uszler JM; Symanowski JT; Ellis PR; Harb WA
Ann Oncol; 2014 Apr; 25(4):852-858. PubMed ID: 24667717
[TBL] [Abstract][Full Text] [Related]
10. Effects of antifolate drugs on the cellular uptake of radiofolates in vitro and in vivo.
Müller C; Brühlmeier M; Schubiger PA; Schibli R
J Nucl Med; 2006 Dec; 47(12):2057-64. PubMed ID: 17138750
[TBL] [Abstract][Full Text] [Related]
11. Patient-specific radiation dosimetry of 99mTc-HYNIC-Tyr3-octreotide in neuroendocrine tumors.
Grimes J; Celler A; Birkenfeld B; Shcherbinin S; Listewnik MH; Piwowarska-Bilska H; Mikolajczak R; Zorga P
J Nucl Med; 2011 Sep; 52(9):1474-81. PubMed ID: 21795364
[TBL] [Abstract][Full Text] [Related]
12. SPECT study of folate receptor-positive malignant and normal tissues in mice using a novel 99mTc-radiofolate.
Müller C; Forrer F; Schibli R; Krenning EP; de Jong M
J Nucl Med; 2008 Feb; 49(2):310-7. PubMed ID: 18199624
[TBL] [Abstract][Full Text] [Related]
13. Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application.
Kemerink GJ; Liu X; Kieffer D; Ceyssens S; Mortelmans L; Verbruggen AM; Steinmetz ND; Vanderheyden JL; Green AM; Verbeke K
J Nucl Med; 2003 Jun; 44(6):947-52. PubMed ID: 12791824
[TBL] [Abstract][Full Text] [Related]
14. Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulated integrin αvβ3-selective radiotracer 99mTc-3PRGD 2 in non-human primates.
Jia B; Liu Z; Zhu Z; Shi J; Jin X; Zhao H; Li F; Liu S; Wang F
Mol Imaging Biol; 2011 Aug; 13(4):730-6. PubMed ID: 20694579
[TBL] [Abstract][Full Text] [Related]
15. Preclinical evaluation of (99m)Tc-EC20 for imaging folate receptor-positive tumors.
Reddy JA; Xu LC; Parker N; Vetzel M; Leamon CP
J Nucl Med; 2004 May; 45(5):857-66. PubMed ID: 15136637
[TBL] [Abstract][Full Text] [Related]
16. [99mTc]demotensin VI: biodistribution and initial clinical results in tumor patients of a pilot/phase I study.
Gabriel M; Decristoforo C; Wöll E; Eisterer W; Nock B; Maina T; Moncayo R; Virgolini I
Cancer Biother Radiopharm; 2011 Oct; 26(5):557-63. PubMed ID: 21883013
[TBL] [Abstract][Full Text] [Related]
17. Imaging of atherosclerosis in apoliprotein e knockout mice: targeting of a folate-conjugated radiopharmaceutical to activated macrophages.
Ayala-López W; Xia W; Varghese B; Low PS
J Nucl Med; 2010 May; 51(5):768-74. PubMed ID: 20395331
[TBL] [Abstract][Full Text] [Related]
18. Folate receptor-targeted radionuclide therapy: preclinical investigation of anti-tumor effects and potential radionephropathy.
Haller S; Reber J; Brandt S; Bernhardt P; Groehn V; Schibli R; Müller C
Nucl Med Biol; 2015 Oct; 42(10):770-9. PubMed ID: 26162583
[TBL] [Abstract][Full Text] [Related]
19. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer.
Vallabhajosula S; Nikolopoulou A; Babich JW; Osborne JR; Tagawa ST; Lipai I; Solnes L; Maresca KP; Armor T; Joyal JL; Crummet R; Stubbs JB; Goldsmith SJ
J Nucl Med; 2014 Nov; 55(11):1791-8. PubMed ID: 25342385
[TBL] [Abstract][Full Text] [Related]
20. Safety, biodistribution and radiation dosimetry of the Arg-Gly-Asp peptide 99m Tc-maraciclatide in healthy volunteers.
Gibbons T; Perkins A; Barnett J
Nucl Med Commun; 2024 Apr; 45(4):295-303. PubMed ID: 38312052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
